- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: AZD0284
Total 260 results
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKUnknownSquamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRASUnited Kingdom
-
AstraZenecaCompleted
-
AstraZenecaTerminatedPlaque Psoriasis VulgarisDenmark
-
AstraZenecaParexelCompletedPlaque Psoriasis VulgarisUnited Kingdom
-
Samsung Medical CenterWithdrawn
-
AstraZenecaParexelRecruitingDilated CardiomyopathyUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditionsUnited States
-
AstraZenecaCompletedHealthy VolunteersUnited States
-
AstraZenecaQuotient SciencesCompleted
-
National Cancer Institute (NCI)Completed
-
AstraZenecaRecruitingB-cell Acute Lymphoblastic Leukemia (B-ALL)Spain, Canada, Korea, Republic of, United Kingdom, Italy, Germany, Australia, China, Taiwan, United States, France
-
Massachusetts General HospitalUnited States Department of Defense; AstraZenecaCompletedMeningioma | Neurofibromatosis 2United States
-
AstraZenecaCompleted
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
AstraZenecaRecruitingMetastatic Prostate CancerUnited States, Australia
-
AstraZenecaCompleted
-
AstraZenecaCompletedNon-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,Japan
-
AstraZenecaNot yet recruitingHepatocellular Carcinoma | Prostate CancerUnited States
-
The Christie NHS Foundation TrustAstraZeneca; University of ManchesterCompleted
-
Massachusetts General HospitalNational Cancer Institute (NCI); AstraZenecaActive, not recruiting
-
Samsung Medical CenterAstraZenecaTerminatedSmall Cell Lung CancerKorea, Republic of
-
AstraZenecaTerminated
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin MelanomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedPrimary Peritoneal Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | Recurrent Borderline Ovarian Surface Epithelial-Stromal TumorUnited States
-
Entasis TherapeuticsCompleted
-
AstraZenecaCompletedMelanoma | Malignant MelanomaUnited Kingdom, Netherlands
-
Children's Hospital Medical Center, CincinnatiAstraZenecaSuspendedGlioma | Ependymoma | Meningioma | Neurofibromatosis 2 | Vestibular SchwannomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Diffuse Large Cell LymphomaUnited States
-
AstraZenecaAstraZeneca K.K.RecruitingDyslipidemiaDenmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingNeurofibromatosis 1 | Plexiform Neurofibroma (PN)United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
-
Samsung Medical CenterWithdrawnSolid TumorKorea, Republic of
-
AstraZenecaActive, not recruitingCancer | TumorUnited States, Netherlands, United Kingdom
-
AstraZenecaCompleted
-
National Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
National Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Neurofibromatosis Type 1 | Refractory Neurofibromatosis Type 1United States
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 | Neurofibroma, Plexiform | Neurofibromatosis Type 1 | NF1United States
-
Merck Sharp & Dohme LLCAstraZenecaCompletedLocally Advanced or Metastatic Solid Tumors
-
AstraZenecaCompletedHealthy Volunteers Pharmacokinetic StudyUnited Kingdom
-
AstraZenecaCompleted
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompletedAdvanced CancerUnited Kingdom
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)WithdrawnNeoplasms, Nerve Tissue | Peripheral Nervous System Diseases | Heredodegenerative Disorders, Nervous System | Neurofibromatosis 1
-
AstraZenecaRecruitingHealthy Participants StudyUnited States
-
King's College LondonAstraZeneca; Helse Stavanger HF; Michael J. Fox Foundation for Parkinson's Research and other collaboratorsWithdrawnParkinson Disease | Mild Cognitive Impairment
-
University of MiamiCompleted
-
AstraZenecaWithdrawnCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma